ArticleClinical transplantation2025
Survival Outcomes of Liver Transplantation Amid Rising Recipient and Donor Risk Profiles.
Article in Clinical transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Transplantation as disease modifying therapy in the era of gene therapy medicinal products - health policy considerations.Orphanet journal of rare diseases · 2026Review
- Ischemic preconditioning promotes hepatic differentiation in human liver organoids.Frontiers in cell and developmental biology · 2026Article
- Donor-derived cell-free DNA as a noninvasive biomarker for diagnosis and monitoring of acute rejection after liver transplantation.Frontiers in immunology · 2026Article
- Survival Outcomes of Liver Transplantation Amid Rising Recipient and Donor Risk Profiles.Clinical transplantation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in liver transplantation (LT) have improved recipients' short-term survival. Whether similar gains extend to long-term outcomes remains unclear.
methodsWe conducted a retrospective analysis of adult, first-time LTs performed in the United States from 2002 to 2018, with follow-up through December 31, 2023. Patients were grouped into three eras: 2002-2007, 2008-2013, and 2014-2018. Exclusions were ABO-incompatible transplants, multivisceral or split grafts, and non-hepatocellular carcinoma malignancies. Survival was estimated with Kaplan-Meier methods; Cox proportional hazards models adjusted for primary indication, sex, Liver Transplant Risk Score (LTRS), and Donor Risk Index (DRI).
resultsAmong 82,696 recipients, 23,656 underwent LT in 2002-2007, 29,355 in 2008-2013, and 29,685 in 2014-2018. Despite increasing LTRS and DRI over time, mortality was significantly lower in 2014-2018 than in earlier eras at 90 days, 1 year, and 5 years (all p < 0.001). Long-term survival improved across all LTRS strata except LTRS ≥ 7. Relative to 2002-2007, adjusted hazards for death were 0.89 (95% CI, 0.87-0.92; p < 0.001) in 2008-2013 and 0.67 (95% CI, 0.64-0.69; p < 0.001) in 2014-2018.
conclusionsDespite rising recipient complexity and broader use of higher-risk donors, both short- and long-term LT survival improved in the United States over the past two decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.